Vertaling van "dataset and meta-analysis " (Frans → Nederlands) :

Bolland MJ, Grey A, Avenell A et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis.
Bolland MJ, Avenell A, Baron JA et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis.

Table 3: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.
Table 1: Search for SR and MA Search Benefit and harms of mammography screening (40-49 y) questions Note Specific search for systematic reviews and meta-analysis Date 19/04/2010 Keywords Breast neoplasms (MESH) and mass screening (or early detection) (MESH) and mammography (MESH) Medline 1 meta-analysis.pt,ti,ab,sh (34320) 27 (1 duplicate) (OVID): 2 1 or (meta anal$ or metaanal$).ti,ab,sh (43943) Filter 3 (methodol$ or systematic$ or quantitativ$).ti,ab,sh.

Table 9: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence
Table 7: Evidence form systematic reviews and meta analysis (breast cancer mortality reduction in intervention group) Study ID Ref Population Intervention Results of meta-analysis Comments Level of evidence

MA=Meta-analysis, SR=Systematic review, MTM=Mixed treatment meta-analysis
MTM= Mixed Treatment Meta-analyse, MA=Meta-analyse, SR= Systematic Review Eyding 2010, Nice 2009, MHRH 2011

(Fernandez 2001) Fernandez E, La Vecchia C, Balducci A et al. Oral contraceptives and colorectal cancer risk: a meta-analysis.
(FSRH POI 2009) Faculty of Sexual and Reproductive Health Care (Royal College of Obstetricians and Gynaecologists).

(Schürks 2009) Schürks M, Rist PM, Bigal ME et al. Migraine and cardiovascular disease: systematic review and meta-analysis.
(Schürks 2009) Schürks M, Rist PM, Bigal ME et al. Migraine and cardiovascular disease: systematic review and meta-analysis. BMJ

Vakil N, Moayyedi P, Fennerty MB et al. limitéd value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis.
Vakil N, Moayyedi P, Fennerty MB et al. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis.

Yu EW, Bauer SR, Bain PA et al. Proton pump inibitors and risk of fractures: a meta-analysis of 11 international studies.
Aseeri M, Schroeder T, Kramer J et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients.

Table 10: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)
Table 8: Evidence form HTA review : Breast cancer screening among women aged 40 – 49 Relative risks (intention to treat) with confidence reported for each study together with the results of a stepwise meta-analysis and cumulative CI Study ID Relative risk Confidence interval Cumulative RR Cumutlative CI UK Age Trial (UK) 0,83 (0,66-1,04) 0,83 (0,66-1,04) NBSS-1 (Canada) 0,97 (0,74-1,27) 0,89 (0,75-1,06) Malmö (Sweden) (0,58-1,77) 0,9 (0,76-1,06) Stockholm (Sweden) 1,08 (0,54-2,17) 0,91 (0,77-1,07) Göteborg (Sweden) 0,65 (0,40-1,05) 0,87 (0,75-1,02) HIP (USA) 0,75 (0,50-1,11) 0,86 (0,74-0,99) TCS (Sweden) 0,93 (0,63-1,36) 0,86 (0,75-0,99) Edinburgh (UK) 0,75 (0.48-1,18) 0,85 (0,75-0,97)

Eom C-S, Jeon CY, Lim J-W et al. Use of acid-suppressive drugs and risk of pneumonia: systematic review and meta-analysis.
Meijvis SSA, Cornips MC, Voorn GP et al. Microbial evaluation of proton pump inhibitors and the risk of pneumonia.